StreetInsider.com News Articles

H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)

Thu, 15 Oct 2026 06:56:21 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Neutral rating and {REMOVEPT} price target on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented: 'Sac-TMT ESMO data could strengthen pembro's position, limiting ivo’s upside even after a positive HARMONi-3 result. On October 13, Merck & Co. (MRK; not rated) confirmed presentations of Phase 3 OptiTROP-Lung06 in 1L PD-L1-negative nonsquamous NSCLC, final OS from OptiTROP-Lung04 in post-EGFR-TKI NSCLC, and global TroFuse-005 results in previously treated endometrial cancer. We believe Lung06 is the most consequential read-through, as sac-TMT + pembro could establish an improved pembro-containing regimen against which ivo’s eventual commercial position would need

Form 4 Summit Therapeutics Inc. For: Oct 08 Filed by: Anand Bhaskar

Wed, 14 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261014/27187187.html

Form PRE 14A Summit Therapeutics Inc. For: Oct 06

Tue, 06 Oct 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20261006/27156267.html

Bernstein SocGen: 'We still think investors should not be long Summit Therapeutics plc (SMMT)'

Mon, 05 Oct 2026 08:19:19 -0400

Bernstein SocGen Group analyst Jeffrey Walch reiterated a Market Perform rating and $11.90 price target on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented: "AZN & Summit collaboration is much ado about nothing in NSCLC - we project negative overall survival for AVANZAR; The third note in our series The Drug Developers: Bringing the Bench to the Buy Side highlights our significant skepticism of an FDA-approved treatment regimen with Datroway and Ivonescimab in NSCLC (AZN and DS announce clinical collaboration with SMMT to evaluate Datroway in combination with ivonescimab across multiple tumour types; AZN/DS covered by Smith/Sogi). A central lesson from

AstraZeneca closes $2 billion equity stake in Summit Therapeutics

Mon, 05 Oct 2026 07:01:11 -0400

AstraZeneca (NYSE: AZN) has completed a $2.0 billion equity investment in Summit Therapeutics Inc. (NASDAQ: SMMT), according to a press release from Summit.

Under the terms of the Securities Purchase Agreement, AstraZeneca purchased approximately 108,955 shares of preferred stock convertible into Summit common stock at a 1:1,000 ratio. The conversion price equates to $18.36 per common share, a premium to the closing trading price on the day the investment was announced.

Summit said the proceeds will support accelerated development of ivonescimab, an investigational PD-1/VEGF bispecific antibody. The drug is being studied across multiple solid tumor indications, including combinations with antibody drug conjugates

AstraZeneca closes $2 billion equity stake in Summit Therapeutics

Mon, 05 Oct 2026 07:01:11 -0400

AstraZeneca (NYSE: AZN) has completed a $2.0 billion equity investment in Summit Therapeutics Inc. (NASDAQ: SMMT), according to a press release from Summit.

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Mon, 05 Oct 2026 07:00:00 -0400

MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody.

Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approximately 108,955 shares of preferred stock convertible into shares of common stock of Summit at a 1:1,000 ratio. The investment by AstraZeneca totaled $2.0 billion. At the conversion ratio, the investment represents a common stock

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Mon, 05 Oct 2026 07:00:00 -0400

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Mon, 05 Oct 2026 07:00:00 -0400

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Mon, 05 Oct 2026 07:00:00 -0400

Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC

Fri, 02 Oct 2026 06:04:31 -0400

Summit Therapeutics Inc. (NASDAQ: SMMT) has entered a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (NYSE: AZN) to evaluate ivonescimab in combination with Datroway (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate, across multiple solid tumor types.

The companies plan to begin with a Phase III trial in first-line triple-negative breast cancer, with intentions to expand into additional tumor settings including lung cancer. Under the agreement, each company will contribute their respective therapies and share trial costs. AstraZeneca or Daiichi Sankyo will sponsor the trials, and each company will retain independent development and commercial rights to their own

Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC

Fri, 02 Oct 2026 06:04:31 -0400

AstraZeneca (AZN) Daiichi Sankyo, AstraZeneca, and Summit to trial Datroway combo

Fri, 02 Oct 2026 02:46:04 -0400

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have signed a clinical trial collaboration agreement with Summit Therapeutics (Nasdaq: SMMT) to evaluate Datroway (datopotamab deruxtecan) in combination with Summit's ivonescimab across multiple tumor types, including lung and breast cancers.

The companies plan to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC). Under the agreement, each company will contribute its respective compound for the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo. All three companies will share trial costs while retaining development and commercial rights to their respective medicines.

Datroway is a TROP2-directed antibody

AstraZeneca (AZN) Daiichi Sankyo, AstraZeneca, and Summit to trial Datroway combo

Fri, 02 Oct 2026 02:46:04 -0400

Datroway is a TROP2-directed antibody

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway